clinical trial · NCT03829579
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
Janssen Research & Development, LLC·—·approved for marketing
Depressive Disorder, Treatment-ResistantEsketamine
brief summary
This is a pre-approval access program (PAAP) for eligible participants. The main purpose of this program is to provide access to esketamine nasal spray to eligible participant with treatment-resistant depression (TRD), who have exhausted all other treatment options, including all alternative treatment options with marketed therapies.
started
—
primary completion
—
completion
—
last updated
Jun 22, 2025
official title
Esketamine Single Patient Request
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol